30/6 2020 19:56 tommycarstensen 0
84886 DSDK Forventes en opjustering?
https://www.ambu.com/corporate-info/investors/news-from-ambu
The sales outlook for the full year was upgraded on 6 April 2020 due to the higher-than-expected growth in Q2. The outlook for organic revenue growth was increased from "16-22%" to "26-30%", and the guidance on the number of endoscopes sold was increased from "approx. 900,000" to "more than 1 million".
The outlook for the EBIT margin before special items was suspended on 6 April 2020 and is now resumed at 12-14%. This interval reflects our decision to accelerate our commercial infrastructure expansion into GI and urology and ensure the successful launches of aScope™ Duodeno and aScope™ 4 Cysto.
The outlook for the financial year 2019/20 is:
Organic growth in the range of 26-30%.
EBIT margin before special items in the range of 12-14%.
Sales of more than 1 million endoscope units.
https://www.ambu.com/corporate-info/investors/news-from-ambu
The sales outlook for the full year was upgraded on 6 April 2020 due to the higher-than-expected growth in Q2. The outlook for organic revenue growth was increased from "16-22%" to "26-30%", and the guidance on the number of endoscopes sold was increased from "approx. 900,000" to "more than 1 million".
The outlook for the EBIT margin before special items was suspended on 6 April 2020 and is now resumed at 12-14%. This interval reflects our decision to accelerate our commercial infrastructure expansion into GI and urology and ensure the successful launches of aScope™ Duodeno and aScope™ 4 Cysto.
The outlook for the financial year 2019/20 is:
Organic growth in the range of 26-30%.
EBIT margin before special items in the range of 12-14%.
Sales of more than 1 million endoscope units.
